EZZ Life Science Holdings Ltd. (AU:EZZ) has released an update.
EZZ Life Science Holdings Ltd. reported a robust financial performance for FY24, with a 78.9% increase in revenue to $66.4m and a 91.8% rise in NPAT to $6.9m. The company has expanded its product range to 53 SKUs, launched in new markets, and is targeting U.S. market growth with upcoming FDA-approved products. EZZ’s strong balance sheet and strategic investments aim to continue revenue growth despite challenging economic conditions.
For further insights into AU:EZZ stock, check out TipRanks’ Stock Analysis page.
